Last reviewed · How we verify
Ibuprofen, Hydrocortisone — Competitive Intelligence Brief
marketed
NSAID + corticosteroid combination
COX-1, COX-2, glucocorticoid receptor
Inflammation, Pain Management
Small molecule
Live · refreshed every 30 min
Target snapshot
Ibuprofen, Hydrocortisone (Ibuprofen, Hydrocortisone) — X-pert Med GmbH. Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, while hydrocortisone suppresses immune and inflammatory responses through glucocorticoid receptor activation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ibuprofen, Hydrocortisone TARGET | Ibuprofen, Hydrocortisone | X-pert Med GmbH | marketed | NSAID + corticosteroid combination | COX-1, COX-2, glucocorticoid receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (NSAID + corticosteroid combination class)
- X-pert Med GmbH · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ibuprofen, Hydrocortisone CI watch — RSS
- Ibuprofen, Hydrocortisone CI watch — Atom
- Ibuprofen, Hydrocortisone CI watch — JSON
- Ibuprofen, Hydrocortisone alone — RSS
- Whole NSAID + corticosteroid combination class — RSS
Cite this brief
Drug Landscape (2026). Ibuprofen, Hydrocortisone — Competitive Intelligence Brief. https://druglandscape.com/ci/ibuprofen-hydrocortisone. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing